JUBBONTI® 60mg

Yes — Jubbonti® (denosumab-bbdz) received FDA approval on March 5, 2024, and is available through licensed distributors. Contact the Doctor Medica team for current supply guidance.

Jubbonti® contains the same active molecule, indications, and dosing as Prolia. FDA biosimilar designation confirms no clinically meaningful differences. The distinction is manufacturer: Sandoz produces Jubbonti®; Amgen produces Prolia.

Jubbonti® is manufactured by Sandoz Inc. and was approved by the FDA on March 5, 2024, as the first interchangeable biosimilar to Prolia. It is distributed through licensed pharmaceutical supply channels.

Jubbonti® 60mg is indicated for postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, and bone loss from androgen deprivation or aromatase inhibitor therapy. It reduces the risk of vertebral, non-vertebral, and hip fractures across these populations.

Common side effects include hypocalcaemia, musculoskeletal pain, and injection site reactions. Serious risks include ONJ, atypical femoral fractures, cellulitis, and rebound bone loss after discontinuation.

Administer the missed dose as soon as possible and reschedule all subsequent doses every 6 months from that date. Patients should notify their doctor or pharmacist to ensure appropriate monitoring.

FDA and EMA biosimilar approval confirms equivalence to Prolia in safety, purity, and potency. Clinical data from the denosumab program, including the landmark FREEDOM trial, demonstrated sustained reductions in fractures and improvements in BMD over 10 years.

1. Jain S. Prevention and management of denosumab discontinuation rebound fractures. Endocrinol Metab Clin North Am. 2024;53(4):559-583. doi:10.1016/j.ecl.2024.08.002
2. Pigni S, Mazziotti G. Management of denosumab discontinuation in clinical practice: in whom, when and how to stop. L’Endocrinologo. 2023;24(1):34-42. doi:10.1007/s40619-023-01207-8
3. Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. The Lancet. 2015;386(9999):1147-1155. doi:10.1016/s0140-6736(15)61120-5
4. Kumar S, Wang M, Kim AS, McDonald MM, Girgis CM. Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures. J Bone Miner Res. 2025;40(9):1017-1034. doi:10.1093/jbmr/zjaf037
Disclaimer
For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.